Cellectis granted U.S. patents for CRISPR T cell therapies

The U.S. Patent Office granted Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) two patents covering the use of RNA-guided endonucleases to develop T cell immunotherapies.

Both patents claim methods of editing T cells using transient expression

Read the full 322 word article

User Sign In